$47.19
0.49% yesterday
Nasdaq, May 20, 09:48 pm CET
ISIN
US69366J2006
Symbol
PTCT
Sector
Industry

PTC Therapeutics, Inc. Stock price

$47.20
-0.99 2.05% 1M
+5.24 12.49% 6M
+2.06 4.56% YTD
+7.08 17.65% 1Y
+14.87 45.99% 3Y
-2.93 5.84% 5Y
-6.74 12.50% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.24 0.51%
ISIN
US69366J2006
Symbol
PTCT
Sector
Industry

Key metrics

Market capitalization $3.74b
Enterprise Value $2.10b
P/E (TTM) P/E ratio 7.25
EV/FCF (TTM) EV/FCF 3.04
EV/Sales (TTM) EV/Sales 1.19
P/S ratio (TTM) P/S ratio 2.11
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 91.12%
Revenue (TTM) Revenue $1.77b
EBIT (operating result TTM) EBIT $868.31m
Free Cash Flow (TTM) Free Cash Flow $693.02m
Cash position $2.03b
EPS (TTM) EPS $6.51
P/E forward 6.11
P/S forward 2.13
EV/Sales forward 1.20
Short interest 7.26%
Show more

Is PTC Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

PTC Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a PTC Therapeutics, Inc. forecast:

10x Buy
63%
5x Hold
31%
1x Sell
6%

Analyst Opinions

16 Analysts have issued a PTC Therapeutics, Inc. forecast:

Buy
63%
Hold
31%
Sell
6%

Financial data from PTC Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1,773 1,773
91% 91%
100%
- Direct Costs 69 69
77% 77%
4%
1,704 1,704
172% 172%
96%
- Selling and Administrative Expenses 281 281
336% 336%
16%
- Research and Development Expense 527 527
10% 10%
30%
896 896
3,631% 3,631%
51%
- Depreciation and Amortization 27 27
89% 89%
2%
EBIT (Operating Income) EBIT 868 868
410% 410%
49%
Net Profit 595 595
203% 203%
34%

In millions USD.

Don't miss a Thing! We will send you all news about PTC Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PTC Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
14 days ago
PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q1 2025 Earnings Call May 6, 2025 4:30 PM ET Company Participants Ellen Cavaleri - Head, Investor Relations Matthew Klein - Chief Executive Officer Eric Pauwels - Chief Business Officer Pierre Gravier - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Eric Joseph - JPMorgan Judah Frommer - Morgan Stanley Geoff Meacham ...
Neutral
PRNewsWire
14 days ago
– Strong revenue performance of $190 million –  – Positive CHMP opinion for Sephience™  (sepiapterin) received in April 2025, NDA review remains on track for July 29, 2025 PDUFA date –  – Global Sephience launch activities progressing well – – Strong cash position of over $2.0 billion as of March 31, 2025 – WARREN, N.J. , May 6, 2025 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today ...
Neutral
PRNewsWire
16 days ago
- Study met primary endpoint with dose-dependent blood HTT protein lowering at Week 12 - - Favorable dose-dependent trends across clinical scales in Stage 2 patients at Month 12 - - Signals of dose-dependent clinical benefit relative to matched natural history cohort as well as dose-dependent lowering of NfL in Stage 2 patients at Month 24 - - Continued favorable safety and tolerability profile...
More PTC Therapeutics, Inc. News

Company Profile

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Head office United States
CEO Matthew Klein
Employees 939
Founded 1998
Website www.ptcbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today